Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

@article{Schreiber2000SafetyAE,
  title={Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.},
  author={Stefan Schreiber and Richard N Fedorak and Ole Haage Nielsen and Gary Wild and Cynthia Williams and Susanna Nikolaus and Meron Jacyna and Bret A. Lashner and Alfred Gangl and P. R. Rutgeerts and Kim E Isaacs and S J Van Deventer and Jacob C. Koningsberger and Marielle Cohard and Alexandre Lebeaut and S B Hanauer},
  journal={Gastroenterology},
  year={2000},
  volume={119 6},
  pages={1461-72}
}
BACKGROUND & AIMS Interleukin (IL)-10 is a cytokine with potent anti-inflammatory properties. We investigated the safety and efficacy of different doses of human recombinant (rhu)IL-10 in patients with Crohn's disease (CD). METHODS A prospective, multicenter, double-blind, placebo-controlled study was conducted in 329 therapy-refractory patients with CD. Clinical improvement was defined by a reduction of the Crohn's Disease Activity Index (CDAI) by 100 points or more and clinical remission by… CONTINUE READING